• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期恶性肿瘤患者发生免疫相关不良事件时的肠道微生物组成。

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events.

机构信息

Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China.

Eight-year Medical Doctor Program, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China.

出版信息

Front Immunol. 2023 Feb 20;14:1109281. doi: 10.3389/fimmu.2023.1109281. eCollection 2023.

DOI:10.3389/fimmu.2023.1109281
PMID:36891304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9986626/
Abstract

INTRODUCTION

The gut microbiota is implicated in the occurrence and severity of immune-related adverse events (irAEs), but the role it plays as well as its causal relationship with irAEs has yet to be established.

METHODS

From May 2020 to August 2021, 93 fecal samples were prospectively collected from 37 patients with advanced thoracic cancers treated with anti-PD-1 therapy, and 61 samples were collected from 33 patients with various cancers developing different irAEs. 16S rDNA amplicon sequencing was performed. Antibiotic-treated mice underwent fecal microbiota transplantation (FMT) with samples from patients with and without colitic irAEs.

RESULTS

Microbiota composition was significantly different in patients with and without irAEs (P=0.001) and with and without colitic-type irAEs (=0.003). , , and were less abundant and more abundant in irAE patients, while and were less abundant and more abundant in colitis-type irAE patients. Major butyrate-producing bacteria were also less abundant in patients with irAEs than those without (P=0.007) and in colitic vs. non-colitic irAE patients (=0.018). An irAE prediction model had an AUC of 86.4% in training and 91.7% in testing. Immune-related colitis was more common in colitic-irAE-FMT (3/9) than non-irAE-FMT mice (0/9).

CONCLUSIONS

The gut microbiota is important in dictating irAE occurrence and type, especially for immune-related colitis, possibly by modulating metabolic pathways.

摘要

简介

肠道微生物群与免疫相关不良事件(irAEs)的发生和严重程度有关,但它的作用及其与 irAEs 的因果关系尚未确定。

方法

2020 年 5 月至 2021 年 8 月,前瞻性收集了 37 例接受抗 PD-1 治疗的晚期胸部恶性肿瘤患者的 93 份粪便样本,以及 33 例发生不同 irAEs 的各种癌症患者的 61 份样本。进行 16S rDNA 扩增子测序。接受抗生素治疗的小鼠接受来自无结肠炎 irAE 患者和有结肠炎 irAE 患者粪便样本的粪便微生物群移植(FMT)。

结果

irAE 患者与无 irAE 患者(P=0.001)和无结肠炎型 irAE 患者与有结肠炎型 irAE 患者(=0.003)的微生物群组成存在显著差异。irAE 患者中, 、 、 丰度较低, 丰度较高,而结肠炎型 irAE 患者中 、 丰度较低, 丰度较高。irAE 患者中主要的丁酸产生菌也比无 irAE 患者(P=0.007)和无结肠炎 vs. 结肠炎 irAE 患者(=0.018)少。irAE 预测模型在训练中的 AUC 为 86.4%,在测试中的 AUC 为 91.7%。在结肠炎 irAE-FMT(3/9)小鼠中,免疫相关结肠炎比非 irAE-FMT 小鼠(0/9)更常见。

结论

肠道微生物群在决定 irAE 的发生和类型方面很重要,特别是对于免疫相关结肠炎,可能通过调节代谢途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/a8c89bbdc1a2/fimmu-14-1109281-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/9900e74ef53e/fimmu-14-1109281-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/c9a7d77c7059/fimmu-14-1109281-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/76ea2bee6025/fimmu-14-1109281-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/d35d7b63f825/fimmu-14-1109281-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/a8c89bbdc1a2/fimmu-14-1109281-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/9900e74ef53e/fimmu-14-1109281-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/c9a7d77c7059/fimmu-14-1109281-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/76ea2bee6025/fimmu-14-1109281-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/d35d7b63f825/fimmu-14-1109281-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e91/9986626/a8c89bbdc1a2/fimmu-14-1109281-g005.jpg

相似文献

1
Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events.晚期恶性肿瘤患者发生免疫相关不良事件时的肠道微生物组成。
Front Immunol. 2023 Feb 20;14:1109281. doi: 10.3389/fimmu.2023.1109281. eCollection 2023.
2
Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events.晚期恶性肿瘤患者在对免疫检查点抑制剂产生继发性耐药和发生免疫相关不良事件时肠道微生物群的动态变化。
Front Oncol. 2023 Apr 11;13:1144534. doi: 10.3389/fonc.2023.1144534. eCollection 2023.
3
Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.抗 PD-1 抑制剂治疗患者的肠道微生物组与免疫相关不良事件相关:一项真实世界研究。
Front Immunol. 2021 Dec 16;12:756872. doi: 10.3389/fimmu.2021.756872. eCollection 2021.
4
Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis.肠道微生物群与基因表达揭示免疫介导性结肠炎和溃疡性结肠炎之间的异同。
Front Oncol. 2021 Oct 27;11:763468. doi: 10.3389/fonc.2021.763468. eCollection 2021.
5
Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models.抗生素相关的菌群失调会影响肠道微生物群在实验性结肠炎模型中进行粪便微生物群移植时控制肠道炎症的能力。
Microbiome. 2021 Feb 6;9(1):39. doi: 10.1186/s40168-020-00991-x.
6
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.PD-1治疗黑色素瘤的免疫相关不良事件及其对抗肿瘤疗效的影响:一项真实世界分析
Front Oncol. 2021 Nov 26;11:749064. doi: 10.3389/fonc.2021.749064. eCollection 2021.
7
irAE-colitis induced by CTLA-4 and PD-1 blocking were ameliorated by TNF blocking and modulation of gut microbial.CTLA-4 和 PD-1 阻断诱导的免疫相关结肠炎通过 TNF 阻断和肠道微生物调节得到改善。
Biomed Pharmacother. 2024 Aug;177:116999. doi: 10.1016/j.biopha.2024.116999. Epub 2024 Jun 25.
8
Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events.跟随肠道菌群:肠道微生物群在预测和治疗免疫相关不良事件中的新兴作用。
Curr Opin Oncol. 2023 Jul 1;35(4):248-253. doi: 10.1097/CCO.0000000000000957. Epub 2023 May 11.
9
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.纳武利尤单抗治疗晚期非小细胞肺癌患者的免疫相关不良反应与临床获益的关联。
Oncologist. 2018 Nov;23(11):1358-1365. doi: 10.1634/theoncologist.2017-0384. Epub 2018 Jun 22.
10
Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.血清生物标志物可预测晚期胃肠道癌患者的免疫相关不良事件和临床获益。
Front Immunol. 2022 Sep 8;13:987568. doi: 10.3389/fimmu.2022.987568. eCollection 2022.

引用本文的文献

1
Immunoenhancing Effect of Lactobacillus Kefiranofaciens ZW18 Postbiotic On Cyclophosphamide-induced Immunosuppressed Mice.发酵乳杆菌ZW18后生元对环磷酰胺诱导的免疫抑制小鼠的免疫增强作用
Probiotics Antimicrob Proteins. 2025 Jun 13. doi: 10.1007/s12602-025-10630-2.
2
Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention.肠道微生物群在免疫相关不良事件中的作用:机制与治疗干预
Nat Rev Clin Oncol. 2025 May 14. doi: 10.1038/s41571-025-01026-w.
3
Gut microbiota in cancer initiation, development and therapy.

本文引用的文献

1
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.结直肠癌和非小细胞肺癌患者在接受西妥昔单抗联合avelumab 治疗时,肠道微生物群与抗肿瘤活性相关。
Int J Cancer. 2022 Aug 1;151(3):473-480. doi: 10.1002/ijc.34033. Epub 2022 Apr 29.
2
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.纳武利尤单抗联合伊匹单抗联合或不联合活菌制剂治疗转移性肾细胞癌的随机 1 期试验。
Nat Med. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28.
3
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
肠道微生物群在癌症的起始、发展和治疗中的作用
Sci China Life Sci. 2024 Dec 30. doi: 10.1007/s11427-024-2831-x.
4
The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment.微生物群对癌症治疗中免疫疗法疗效和毒性的影响。
Mol Biol Rep. 2024 Dec 26;52(1):86. doi: 10.1007/s11033-024-10188-2.
5
Unraveling the role of gut microbiome in predicting adverse events in neoadjuvant therapy for rectal cancer.揭示肠道微生物群在预测直肠癌新辅助治疗不良事件中的作用。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2430087. doi: 10.1080/21645515.2024.2430087. Epub 2024 Dec 2.
6
Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors.肠道微生物组代谢物、分子模拟和种属水平变异可影响肺癌幸存者的长期疗效和不良事件结局。
EBioMedicine. 2024 Nov;109:105427. doi: 10.1016/j.ebiom.2024.105427. Epub 2024 Oct 30.
7
Gastrointestinal cancer resistance to treatment: the role of microbiota.胃肠道癌症的治疗耐药性:微生物群的作用
Infect Agent Cancer. 2024 Oct 5;19(1):50. doi: 10.1186/s13027-024-00605-3.
8
Efficacy and regulatory strategies of gut microbiota in immunotherapy: a narrative review.肠道微生物群在免疫治疗中的功效及调控策略:一篇叙述性综述
Transl Cancer Res. 2024 Apr 30;13(4):2043-2063. doi: 10.21037/tcr-24-316. Epub 2024 Apr 15.
9
Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy.基于PD-1受体/配体靶向癌症免疫疗法探索肠道菌群的调控机制
Front Immunol. 2024 Mar 28;15:1359029. doi: 10.3389/fimmu.2024.1359029. eCollection 2024.
10
Two cases of severe oral mucositis caused by atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma.两例由阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌引起的严重口腔黏膜炎。
Clin J Gastroenterol. 2024 Jun;17(3):523-529. doi: 10.1007/s12328-024-01947-6. Epub 2024 Mar 21.
抗 PD-1 治疗的黑色素瘤患者临床应答和免疫相关不良事件的肠道微生物组特征
Nat Med. 2022 Mar;28(3):545-556. doi: 10.1038/s41591-022-01698-2. Epub 2022 Feb 28.
4
Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages.普雷沃氏菌科通过 PPARα-CYP4X1 轴在结肠巨噬细胞中产生丁酸盐来缓解 PD-1/PD-L1 抑制剂相关的心脏毒性。
J Exp Clin Cancer Res. 2022 Jan 3;41(1):1. doi: 10.1186/s13046-021-02201-4.
5
Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.抗 PD-1 抑制剂治疗患者的肠道微生物组与免疫相关不良事件相关:一项真实世界研究。
Front Immunol. 2021 Dec 16;12:756872. doi: 10.3389/fimmu.2021.756872. eCollection 2021.
6
Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis.肠道微生物群与基因表达揭示免疫介导性结肠炎和溃疡性结肠炎之间的异同。
Front Oncol. 2021 Oct 27;11:763468. doi: 10.3389/fonc.2021.763468. eCollection 2021.
7
Allicin Ameliorates Intestinal Barrier Damage via Microbiota-Regulated Short-Chain Fatty Acids-TLR4/MyD88/NF-κB Cascade Response in Acrylamide-Induced Rats.大蒜素通过菌群调节的短链脂肪酸-TLR4/MyD88/NF-κB 级联反应缓解丙烯酰胺诱导的大鼠肠道屏障损伤。
J Agric Food Chem. 2021 Nov 3;69(43):12837-12852. doi: 10.1021/acs.jafc.1c05014. Epub 2021 Oct 25.
8
Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.脆弱拟杆菌和多形拟杆菌预测免疫检查点阻断治疗转移性黑色素瘤的免疫相关不良事件。
Genome Med. 2021 Oct 13;13(1):160. doi: 10.1186/s13073-021-00974-z.
9
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.肠道微生物组特征与 CTLA-4 和 PD-1 联合阻断的毒性相关。
Nat Med. 2021 Aug;27(8):1432-1441. doi: 10.1038/s41591-021-01406-6. Epub 2021 Jul 8.
10
Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8 T cell immunity.肠道微生物代谢物通过调节细胞毒性 CD8 T 细胞免疫来促进癌症治疗疗效。
Cell Metab. 2021 May 4;33(5):988-1000.e7. doi: 10.1016/j.cmet.2021.03.002. Epub 2021 Mar 23.